159 related articles for article (PubMed ID: 8975383)
1. [Loss of extremities caused by heparin-induced thrombocytopenia].
Wenzl ME; Leffringhausen W; Scherlitzky L
Unfallchirurg; 1996 Aug; 99(8):607-11. PubMed ID: 8975383
[TBL] [Abstract][Full Text] [Related]
2. The use of low dose Orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations.
Hill GR; Hickton C; Henderson S; Patton WN
Clin Lab Haematol; 1997 Jun; 19(2):155-7. PubMed ID: 9218159
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolic prophylaxis with danaparoïd (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease.
Macchi L; Sarfati R; Guicheteau M; Chamlian V; Pourrat O; Gruel Y; Magnin G; Brizard A; Boinot C
Clin Appl Thromb Hemost; 2000 Oct; 6(4):187-9. PubMed ID: 11030522
[TBL] [Abstract][Full Text] [Related]
4. The management of heparin-induced thrombocytopenia.
Keeling D; Davidson S; Watson H;
Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
[TBL] [Abstract][Full Text] [Related]
5. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
[TBL] [Abstract][Full Text] [Related]
6. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
Kodityal S; Manhas AH; Udden M; Rice L
Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
[TBL] [Abstract][Full Text] [Related]
7. [Current recommendations for diagnosis and therapy of heparin-induced thrombocytopenia].
Hinz P; Lubenow N; Eckernkamp A; Geinacher A
Unfallchirurg; 2002 Sep; 105(9):845-50. PubMed ID: 12232745
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
[TBL] [Abstract][Full Text] [Related]
9. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
Farner B; Eichler P; Kroll H; Greinacher A
Thromb Haemost; 2001 Jun; 85(6):950-7. PubMed ID: 11434701
[TBL] [Abstract][Full Text] [Related]
10. [Heparin-induced thrombocytopenia occurring after surgical treatment of atrial myxoma--a case report].
Djunić I; Tomin D; Antonijević N; Gradinac S; Kovac M; Vidović A; Djurasinović V; Elezović I
Srp Arh Celok Lek; 2009; 137(9-10):540-4. PubMed ID: 19950764
[TBL] [Abstract][Full Text] [Related]
11. Lifesaving citrate anticoagulation to bridge ineffective danaparoid [correction of to bridge to danaparoid] treatment.
Dworschak M; Hiesmayr JM; Lassnigg A
Ann Thorac Surg; 2002 May; 73(5):1626-7. PubMed ID: 12022563
[TBL] [Abstract][Full Text] [Related]
12. Heparin-induced thrombocytopenia and thrombosis.
Patel VP; Bong M; Di Cesare PE
Am J Orthop (Belle Mead NJ); 2007 May; 36(5):255-60. PubMed ID: 17571830
[TBL] [Abstract][Full Text] [Related]
13. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II.
Zöhrer' B; Zenz W; Rettenbacher A; Covi P; Kurnik K; Kroll H; Grubbauer HM; Muntean W
Acta Paediatr; 2001 Jul; 90(7):765-71. PubMed ID: 11519979
[TBL] [Abstract][Full Text] [Related]
14. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management.
Shantsila E; Lip GYH; Chong BH
Chest; 2009 Jun; 135(6):1651-1664. PubMed ID: 19497901
[TBL] [Abstract][Full Text] [Related]
15. [Heparin-induced thrombocytopenia--a serious complication within the scope of heparin therapy. Follow-up of 7 trauma surgery patients].
Kuhn B
Unfallchirurg; 1997 Aug; 100(8):646-51. PubMed ID: 9381213
[TBL] [Abstract][Full Text] [Related]
16. Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management.
Januzzi JL; Jang IK
J Thromb Thrombolysis; 1999 Jun; 7(3):259-64. PubMed ID: 10375387
[TBL] [Abstract][Full Text] [Related]
17. Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report.
Horlait G; Minet V; Mullier F; Michaux I
Blood Coagul Fibrinolysis; 2017 Mar; 28(2):193-197. PubMed ID: 27100305
[TBL] [Abstract][Full Text] [Related]
18. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study.
Chong BH; Gallus AS; Cade JF; Magnani H; Manoharan A; Oldmeadow M; Arthur C; Rickard K; Gallo J; Lloyd J; Seshadri P; Chesterman CN;
Thromb Haemost; 2001 Nov; 86(5):1170-5. PubMed ID: 11816702
[TBL] [Abstract][Full Text] [Related]
19. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C
Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
[TBL] [Abstract][Full Text] [Related]
20. A comparative review of the adverse effect profiles of heparins and heparinoids.
Borris LC; Lassen MR
Drug Saf; 1995 Jan; 12(1):26-31. PubMed ID: 7537967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
